As for the POEMS trial that included patients with stage I-IIIA oestrogen and progesterone negative breast cancer, patients receiving GnRH agonist in addition to chemotherapy were more likely to experience a pregnancy with a 23.1% 5-year cumulative incidence compared to only 12.2% in chemotherapy alone (p = 0.03) [46]. The gene discussed is GNRH1; the disease is breast cancer.